Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of HPV-negative head and neck squamous cell carcinoma
Economic burden and healthcare resource utilization
7 evidence topics · 7 sources
Monthly cost of care in recurrent or refractory disease in US community oncology
“This retrospective observational study was conducted by using data from the Vector Oncology Data Warehouse.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Through the overall study period (mean, 20.5 months), 74% of patients were hospitalized, 19% had an emergency department visit, and 100% had an office visit.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean monthly health care cost for the overall study period was $14,391 (95% CI, 12,739-16,044). Hospitalization costs represented ~57% of the total expenditures.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Resource use and costs before and after immuno-oncology agents
“Of 716 patients identified (pre-IO = 265, post-IO = 451) 46.3% of post-IO patients received IO post-platinum.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Inpatient admissions during 1 L PPT: 34.1% post-IO versus 48.0% pre-IO (p= <.01). PPPM total costs of care in 1 L PPT were significantly greater post-IO ($11,535) compared to pre-IO ($9,054, p=.002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Incremental costs of metastatic and recurrent disease in Medicare and commercial claims
“Administrative claims from Medicare- and privately-insured individuals during 2004-2008 were used in this retrospective database study of patients with advanced HNC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 6-month incremental adjusted total costs were $60,414 per patient for mHNC and $21,141 per patient for rHNC (p<0.0001). Approximately 46-58% of the incremental cost was attributable to outpatient visits, 27-37% to inpatient costs and 11-13% to pharmacy, depending on the HNC cohort.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Costs associated with recurrence in older patients in SEER-Medicare
“Older patients diagnosed with LA HNSCC (2007-2019) from the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recurrence was associated with higher HCRU and monthly health care costs in both resected ($3,831; 95% CI = $2,319-$5,360) and unresected ($4,730; 95% CI = $3,611-$5,870) groups (P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of head and neck cancer costs
“Data from these studies suggested that costs generally are higher for HNC patients with recurrent and/or metastatic disease, for patients undergoing surgery, and for those patients insured by private payers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of first-line pembrolizumab from a US payer perspective
“A three-state partitioned-survival model was used to project costs and outcomes over 20 years with 3% annual discounting.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the CPS ≥1 R/M HNSCC population, pembrolizumab monotherapy was dominant vs. EXTREME and TPEx regimens, and cost-effective (at $100,000/QALY threshold) vs. platinum+5-FU ($86,827/QALY) and cisplatin + paclitaxel ($81,473/QALY).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pembrolizumab combination therapy in the overall R/M HNSCC population was dominant vs. TPEx regimen, and cost-effective vs. EXTREME regimen ($1769/QALY), platinum+5-FU ($81,989/QALY), and cisplatin + paclitaxel ($89,505/QALY).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of first-line pembrolizumab by PD-L1 combined positive score
“When compared with cetuximab plus chemotherapy, the pembrolizumab monotherapy strategy was dominated by lower cost and better efficacy in all three populations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incremental costs and quality adjusted life years (QALYs) yielded by pembrolizumab plus chemotherapy compared with cetuximab plus chemotherapy were $16016.88 and 0.11 in the total population, and $24467.47 and 0.18 and $30448.46 and 0.20 in the populations with a PD-L1 CPS ≥ 1 and CPS ≥ 20, respectively, leading to ICERs of $147876.14, $134237.84, and $153660.78 per QALY, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote